







an Open Access Journal by MDPI

Advances in Prognosis and Theranostics of Cancer

Guest Editors:

Dr. Sudip Mukherjee

Department of Bioengineering, Rice University, 6500 Main Street, Houston, TX 77005, USA

Dr. Manash Paul

Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, The University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Deadline for manuscript submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

Cancer is one of the leading causes of death worldwide. As per the recent cancer statistics data, cancer accounts for an estimated 18.1 million cancer cases and 9.5 million deaths in 2018. Although advances have been made in the treatment of cancers, there are still many existing challenges mainly due to the lack of an early diagnosis and inefficiency in conventional therapies, which causes poor prognosis and overall survival of cancer patients.

Hence alternative prognostic, therapeutic, and diagnostic approaches are required to reduce overall mortality and improve patient quality of life. In this present issue, we will publish research, reviews, and short communications on the modern approaches to combat cancer. Contributions on biomarker discovery, diagnosis, therapeutic modalities including immunotherapy, cancer vaccines, biomaterials-based theranostics approaches, nanomedicine-based theranostics, small molecule-based targeting, immunomodulatory approaches and other emergent approaches in precision oncology are also encouraged.

Dr. Sudip Mukherjee Dr. Manash Paul Guest Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us